Novartis AG Stock

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 05:15:37 2024-07-08 am EDT 5-day change 1st Jan Change
97.1 CHF +0.51% Intraday chart for Novartis AG +0.39% +14.41%
Sales 2024 * 49.22B 44.08B Sales 2025 * 51.36B 46B Capitalization 220B 197B
Net income 2024 * 10.68B 9.57B Net income 2025 * 11.97B 10.72B EV / Sales 2024 * 4.73 x
Net Debt 2024 * 13.39B 11.99B Net Debt 2025 * 11.66B 10.45B EV / Sales 2025 * 4.5 x
P/E ratio 2024 *
20.9 x
P/E ratio 2025 *
18.1 x
Employees 76,057
Yield 2024 *
3.4%
Yield 2025 *
3.53%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.56%
1 week+0.39%
Current month+0.97%
1 month+2.97%
3 months+12.45%
6 months+6.94%
Current year+14.41%
More quotes
1 week
95.52
Extreme 95.52
97.64
1 month
92.76
Extreme 92.76
97.64
Current year
83.63
Extreme 83.63
97.64
1 year
83.00
Extreme 83
97.64
3 years
72.84
Extreme 72.84
97.64
5 years
65.09
Extreme 65.09
97.64
10 years
65.09
Extreme 65.09
103.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Date Price Change Volume
24-07-08 97.02 +0.42% 319 075
24-07-05 96.61 -0.65% 2,230,130
24-07-04 97.24 +1.18% 2,106,530
24-07-03 96.11 -0.36% 2,139,549
24-07-02 96.46 -0.27% 2,628,827

Delayed Quote Swiss Exchange, July 08, 2024 at 05:00 am EDT

More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107.7 USD
Average target price
111 USD
Spread / Average Target
+3.13%
Consensus